Lista de obras - Alessandra Romano - Dominio Público Uruguay

A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents

artículo científico publicado en 2020

A snapshot of asparaginase-induced liver insufficiency.

artículo científico publicado en 2014

Acute GVHD after allogeneic hematopoietic transplantation affects early marrow reconstitution and speed of engraftment

artículo científico publicado en 2015

Advances in understanding regulatory myeloid cells

artículo científico publicado en 2011

Antiproliferative and Antiangiogenic Effects of Punica granatum Juice (PGJ) in Multiple Myeloma (MM)

scientific article published on October 2016

Aplastic Anemia & MDS International Foundation (AA&MDSIF): bone marrow failure disease scientific symposium 2012.

artículo científico publicado en 2013

Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial

scientific article published on 31 January 2011

Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells.

artículo científico publicado en 2015

Broad copy neutral-loss of heterozygosity regions and rare recurring copy number abnormalities in normal karyotype-acute myeloid leukemia genomes.

artículo científico publicado en 2010

CD200 expression in patients with Multiple Myeloma: another piece of the puzzle.

artículo científico publicado en 2013

Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies.

artículo científico publicado en 2016

Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy.

artículo científico publicado en 2014

Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients

scientific article published on 16 October 2019

Clinical Impact of the Immunome in Lymphoid Malignancies: The Role of Myeloid-Derived Suppressor Cells

artículo científico publicado en 2015

Clonal selection of 11q CN-LOH and CBL gene mutation in a serially studied patient during MDS progression to AML

artículo científico publicado en 2010

Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients

artículo científico publicado en 2011

Endoscopic features of gastro-intestinal lymphomas: from diagnosis to follow-up

artículo científico publicado en 2014

Endoscopic ultrasonography in gastric lymphomas: appraisal on reliability in long-term follow-up

artículo científico publicado en 2011

Energy dynamics for systemic configurations of virus-host co-evolution

artículo científico publicado en 2020

Erythrocytapheresis is a valid and safe therapeutic option in dysmetabolic iron overload syndrome

artículo científico publicado en 2015

Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network

scientific article published on 19 June 2019

Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC)

artículo científico publicado en 2016

Heme oxygenase-1 nuclear translocation regulates bortezomibinduced cytotoxicity and mediates genomic instability in myeloma cells

artículo científico publicado en 2016

High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib

scientific article published on February 2014

Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells.

artículo científico publicado en 2011

Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma

artículo científico publicado en 2019

Immunological deregulation in classic hodgkin lymphoma.

artículo científico publicado en 2014

Immunological dysregulation in multiple myeloma microenvironment.

artículo científico publicado en 2014

Immunoproteasome Genes Are Modulated in CD34+ JAK2V617F Mutated Cells from Primary Myelofibrosis Patients

scientific article published on 22 April 2020

Inhibition of TLR4 Signaling Affects Mitochondrial Fitness and Overcomes Bortezomib Resistance in Myeloma Plasma Cells

artículo científico publicado en 2020

Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma

artículo científico publicado en 2012

Ixazomib Improves Bone Remodeling and Counteracts sonic Hedgehog signaling Inhibition Mediated by Myeloma Cells

scientific article published on 30 January 2020

Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients

artículo científico publicado en 2016

Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells

artículo científico publicado en 2020

Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies ⬇️

artículo científico publicado en 2019

Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients.

artículo científico publicado en 2014

NF-κB localization in multiple myeloma plasma cells and mesenchymal cells.

artículo científico publicado en 2010

Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents

artículo científico publicado en 2015

PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy.

artículo científico publicado en 2018

Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy Via STAT3

scientific article published on 19 July 2019

Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma.

artículo científico publicado en 2017

Prognostic assessment and treatment of primary gastric lymphomas: how endoscopic ultrasonography can help in tailoring patient management

artículo científico publicado en 2013

Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy.

artículo científico publicado en 2018

Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacitidine in High-Risk Myelodysplasia.

artículo científico publicado en 2017

Salvage therapy of multiple myeloma: the new generation drugs

artículo científico

Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients.

artículo científico publicado en 2014

Standard therapies versus novel therapies in Hodgkin lymphoma.

artículo científico publicado en 2013

The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis

artículo científico publicado en 2019

The Role of Inflammation and Inflammasome in Myeloproliferative Disease

scientific article published on 22 July 2020

The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study.

artículo científico publicado en 2016

The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma

artículo científico publicado en 2016

The neutrophil to lymphocyte ratio (NLR) and the presence of large nodal mass are independent predictors of early response: A subanalysis of the prospective phase II PET-2-adapted HD0607 trial

artículo científico publicado en 2020

The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma

artículo científico publicado en 2016

Lista de obras de Alessandra Romano

A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents

A snapshot of asparaginase-induced liver insufficiency.

Acute GVHD after allogeneic hematopoietic transplantation affects early marrow reconstitution and speed of engraftment

Advances in understanding regulatory myeloid cells

Antiproliferative and Antiangiogenic Effects of Punica granatum Juice (PGJ) in Multiple Myeloma (MM)

Aplastic Anemia & MDS International Foundation (AA&MDSIF): bone marrow failure disease scientific symposium 2012.

Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial

Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells.

Broad copy neutral-loss of heterozygosity regions and rare recurring copy number abnormalities in normal karyotype-acute myeloid leukemia genomes.

CD200 expression in patients with Multiple Myeloma: another piece of the puzzle.

Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies.

Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy.

Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients

Clinical Impact of the Immunome in Lymphoid Malignancies: The Role of Myeloid-Derived Suppressor Cells

Clonal selection of 11q CN-LOH and CBL gene mutation in a serially studied patient during MDS progression to AML

Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients

Endoscopic features of gastro-intestinal lymphomas: from diagnosis to follow-up

Endoscopic ultrasonography in gastric lymphomas: appraisal on reliability in long-term follow-up

Energy dynamics for systemic configurations of virus-host co-evolution

Erythrocytapheresis is a valid and safe therapeutic option in dysmetabolic iron overload syndrome

Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network

Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC)

Heme oxygenase-1 nuclear translocation regulates bortezomibinduced cytotoxicity and mediates genomic instability in myeloma cells

High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib

Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells.

Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma

Immunological deregulation in classic hodgkin lymphoma.

Immunological dysregulation in multiple myeloma microenvironment.

Immunoproteasome Genes Are Modulated in CD34+ JAK2V617F Mutated Cells from Primary Myelofibrosis Patients

Inhibition of TLR4 Signaling Affects Mitochondrial Fitness and Overcomes Bortezomib Resistance in Myeloma Plasma Cells

Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma

Ixazomib Improves Bone Remodeling and Counteracts sonic Hedgehog signaling Inhibition Mediated by Myeloma Cells

Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients

Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells

Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies ⬇️

Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients.

NF-κB localization in multiple myeloma plasma cells and mesenchymal cells.

Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents

PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy.

Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy Via STAT3

Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma.

Prognostic assessment and treatment of primary gastric lymphomas: how endoscopic ultrasonography can help in tailoring patient management

Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy.

Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacitidine in High-Risk Myelodysplasia.

Salvage therapy of multiple myeloma: the new generation drugs

Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients.

Standard therapies versus novel therapies in Hodgkin lymphoma.

The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis

The Role of Inflammation and Inflammasome in Myeloproliferative Disease

The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study.

The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma

The neutrophil to lymphocyte ratio (NLR) and the presence of large nodal mass are independent predictors of early response: A subanalysis of the prospective phase II PET-2-adapted HD0607 trial

The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma